The Observer A.I Power Index 2025, published by Observer, the digital media chronicling the world's power players, has officially been released, recognizing 100 global leaders driving the future of artificial intelligence across industries. Insilico Medicine's founder, CEO & CBO, Alex Zhavoronkov, PhD, was selected for his unique contributions at the intersection of biotechnology and AI.
Upon evaluation of each individual by their influence on technologies, markets, and policies, the Observer AI Power Index named industry leaders including Sam Altman, co-founder and CEO of OpenAI; Jensen Huang, co-founder, president, and CEO of Nvidia; Satya Nadella, CEO of Microsoft; Sundar Pichai, CEO of Google and Alphabet; and Demis Hassabis, the 2024 Nobel Prize in Chemistry laureate, CEO and co-founder of Google DeepMind.
Alex Zhavoronkov, PhD, is founder of Insilico Medicine and a multiple-time Clarivate Highly Cited Researcher, who led the establishment and advancement of Pharma.AI, a generative AI-powered solution spanning biology, chemistry, medicine development, and science research. Since 2021, Pharma.AI empowered 30+ self-developed, comprehensive, innovative drug pipelines of Insilico, with 10 received IND clearance. In June 2025, Insilico's leading Rentosertib (ISM001-055) was published in Nature Medicine, with Phase IIa clinical data demonstrating potential signs of lung function restoration measured by improved Forced Vital Capacity (FVC) in idiopathic pulmonary fibrosis (IPF) patients, marking the first clinical proof-of-concept for AI-driven drug development.
Speaking with Observer, Dr. Zhavoronkov emphasized, “We're heading into an era of pharmaceutical superintelligence, where agents won't just streamline workflows but actually make decisions and design experiments. Most people aren't talking about it yet, but once AI starts managing AI, everything changes.”
Harnessing state-of-the-art AI and automated technologies, Insilico has significantly improved the efficiency of preclinical drug development. From 2021 to 2024, Insilico nominated 20+ preclinical candidates, achieving an average turnaround—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com